DSM-Firmenich AG's revenue for the
six
months ended in Dec. 2025 was CHF2,355 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was CHF8,461 Mil.
DSM-Firmenich AG's Revenue per Share for the
six
months ended in Dec. 2025 was CHF9.23.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF32.40.
Warning Sign:
DSM-Firmenich AG revenue per share has been in decline over the past 3 years.
During the past 4 years, DSM-Firmenich AG's highest 3-Year average Revenue per Share Growth Rate was -22.90% per year. The lowest was -22.90% per year. And the median was -22.90% per year.
DSM-Firmenich AG (XSWX:DSFIR) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
DSM-Firmenich AG Revenue Related Terms
DSM-Firmenich AG Revenue Historical Data
* Premium members only.
The historical data trend for DSM-Firmenich AG's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, DSM-Firmenich AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DSM-Firmenich AG Revenue vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, DSM-Firmenich AG's Revenue distribution charts can be found below:
* The bar in red indicates where DSM-Firmenich AG's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF8,461 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DSM-Firmenich AG (XSWX:DSFIR) has a Revenue of CHF8,461 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on DSM-Firmenich AG and its competitors.
Is DSM-Firmenich AG's Revenue too high?
DSM-Firmenich AG's current Revenue is CHF8,461 Mil. Overall, DSM-Firmenich AG has a GF Score™ of 32/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DSM-Firmenich AG's Revenue compare to LIN and SHW?
DSM-Firmenich AG's Revenue of CHF8,461 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Chemicals company?
A good Revenue depends on the Chemicals industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on DSM-Firmenich AG and its competitors. DSM-Firmenich AG's current Revenue is CHF8,461 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DSM-Firmenich AG stock overvalued right now?
Based on GuruFocus' analysis, DSM-Firmenich AG (XSWX:DSFIR) is currently considered Fairly Valued. The stock's GF Value™ is CHF70.90, compared to a current price of CHF74.82 — trading 5.5% above its estimated fair value. The current Revenue is CHF8,461 Mil. DSM-Firmenich AG's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For DSM-Firmenich AG (XSWX:DSFIR), the current Revenue is CHF8,461 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DSM-Firmenich AG (XSWX:DSFIR) Overvalued in 2026?
Based on GuruFocus' analysis, DSM-Firmenich AG stock appears to be overvalued.
The current stock price of CHF74.82 is trading 5.5% above its estimated GF Value™ of CHF70.90.
GuruFocus considers DSM-Firmenich AG to be Fairly Valued.
Key valuation signals for XSWX:DSFIR:
Revenue: CHF8,461 Mil
GF Value™: CHF70.90 vs. price of CHF74.82 (5.5% above fair value)
No single metric tells the full story. See the XSWX:DSFIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DSM-Firmenich is a global science-based company formed in 2023 through the merger of DSM, a Dutch nutrition, health, and sustainable living player, and Switzerland-based Firmenich, the third-largest player in the flavor and fragrance market. The company serves a wide range of end-consumer markets providing nutrition solutions ranging from medical and early-life nutrition, fragrances for personal-, home-, and laundry-care brands, prestige perfumes, and other ingredients for food and beverage, home, and personal care. DSM-Firmenich has nearly 30,000 employees, with more than 2,000 scientists and engineers spread across 15 research and development facilities.
32GF Score
Get the complete analysis for XSWX:DSFIR
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DSFIR has been successfully added to your 